

Douglas H Thamm

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6661339/douglas-h-thamm-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

192
papers

6,704
citations

42
h-index

76
g-index

209
ext. papers

7,721
ext. citations

3.6
avg, IF

5.87
L-index

#	Paper	IF	Citations
192	The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 13075-80	11.5	1095
191	Polymer-modified gadolinium metal-organic framework nanoparticles used as multifunctional nanomedicines for the targeted imaging and treatment of cancer. <i>Biomacromolecules</i> , 2009 , 10, 983-93	6.9	232
190	Autophagy and cancer therapy. <i>Molecular Pharmacology</i> , 2014 , 85, 830-8	4.3	225
189	Evaluation of a 6-Month Chemotherapy Protocol with No Maintenance Therapy for Dogs with Lymphoma. <i>Journal of Veterinary Internal Medicine</i> , 2002 , 16, 704-709	3.1	216
188	Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. <i>Veterinary and Comparative Oncology</i> , 2015 , 13, 176-83	2.5	206
187	An asymmetric synthesis of 1,2,4-trioxane anticancer agents via desymmetrization of peroxyquinols through a Brønsted acid catalysis cascade. <i>Journal of the American Chemical Society</i> , 2012 , 134, 13554-7	16.4	174
186	Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours. <i>Veterinary and Comparative Oncology</i> , 2012 , 10, 194-205	2.5	136
185	Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. <i>Autophagy</i> , 2014 , 10, 1415-25	10.2	124
184	Systemic administration of an attenuated, tumor-targeting <i>Salmonella typhimurium</i> to dogs with spontaneous neoplasia: phase I evaluation. <i>Clinical Cancer Research</i> , 2005 , 11, 4827-34	12.9	115
183	Tuning the magnetic resonance imaging properties of positive contrast agent nanoparticles by surface modification with RAFT polymers. <i>Langmuir</i> , 2009 , 25, 9487-99	4	106
182	IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. <i>Journal of Cellular Biochemistry</i> , 2004 , 92, 77-91	4.7	105
181	Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. <i>Journal of Veterinary Medical Science</i> , 2006 , 68, 581-7	1.1	97
180	Carcinoma of the apocrine glands of the anal sac in dogs: 113 cases (1985-1995). <i>Journal of the American Veterinary Medical Association</i> , 2003 , 223, 825-31	1	94
179	Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. <i>PLoS ONE</i> , 2009 , 4, e4972	3.7	93
178	Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma. <i>Journal of Veterinary Internal Medicine</i> , 2014 , 28, 554-63	3.1	91
177	Prednisone and Vinblastine Chemotherapy for Canine Mast Cell Tumor--41 Cases (1992-1997). <i>Journal of Veterinary Internal Medicine</i> , 1999 , 13, 491-497	3.1	90
176	Prednisone and vinblastine chemotherapy for canine mast cell tumor--41 cases (1992-1997). <i>Journal of Veterinary Internal Medicine</i> , 1999 , 13, 491-7	3.1	86

175	Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology. <i>Science Translational Medicine</i> , 2016 , 8, 324ps5	17.5	85
174	Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma. <i>Journal of Veterinary Internal Medicine</i> , 2011 , 25, 920-6	3.1	82
173	Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. <i>Journal of Veterinary Internal Medicine</i> , 2002 , 16, 704-9	3.1	78
172	Bisphosphonate conjugation for bone specific drug targeting. <i>Bone Reports</i> , 2018 , 9, 47-60	2.6	76
171	Liposome-Encapsulated Doxorubicin (Doxil) and Doxorubicin in the Treatment of Vaccine-Associated Sarcoma in Cats. <i>Journal of Veterinary Internal Medicine</i> , 2002 , 16, 726-731	3.1	73
170	Glycolysis inhibition by 2-deoxy-D-glucose reverts the metastatic phenotype in vitro and in vivo. <i>Clinical and Experimental Metastasis</i> , 2011 , 28, 865-75	4.7	70
169	Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. <i>Journal of Veterinary Internal Medicine</i> , 2012 , 26, 355-62	3.1	69
168	Does L-Asparaginase Influence Efficacy or Toxicity When Added to a Standard CHOP Protocol for Dogs with Lymphoma?. <i>Journal of Veterinary Internal Medicine</i> , 2005 , 19, 732-736	3.1	69
167	Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2004 , 54, 25-33	3.5	69
166	GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. <i>Clinical Cancer Research</i> , 2008 , 14, 2824-32	12.9	67
165	Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004). <i>Journal of the American Veterinary Medical Association</i> , 2006 , 228, 91-5	1	65
164	Recommended guidelines for the conduct and evaluation of prognostic studies in veterinary oncology. <i>Veterinary Pathology</i> , 2011 , 48, 7-18	2.8	61
163	Correlation of nodal mast cells with clinical outcome in dogs with mast cell tumour and a proposed classification system for the evaluation of node metastasis. <i>Journal of Comparative Pathology</i> , 2014 , 151, 329-38	1	59
162	Mast Cell Tumors 2007 , 402-424		59
161	c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. <i>Clinical and Experimental Metastasis</i> , 2003 , 20, 421-30	4.7	56
160	Evaluation of a Novel Tumor Vaccine in Dogs with Hemangiosarcoma. <i>Journal of Veterinary Internal Medicine</i> , 2007 , 21, 113-120	3.1	55
159	The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 83-92	3.5	50
158	Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma. <i>Clinical Cancer Research</i> , 2009 , 15, 3503-10	12.9	49

157	A temporary indwelling intravascular aphaeretic system for in vivo enrichment of circulating tumor cells. <i>Nature Communications</i> , 2019 , 10, 1478	17.4	45
156	Increased monocyte chemotactic protein-1 concentration and monocyte count independently associate with a poor prognosis in dogs with lymphoma. <i>Veterinary and Comparative Oncology</i> , 2011 , 9, 55-64	2.5	45
155	Association of blood monocyte and lymphocyte count and disease-free interval in dogs with osteosarcoma. <i>Journal of Veterinary Internal Medicine</i> , 2010 , 24, 1439-44	3.1	45
154	Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 1299-309	7.4	45
153	Combination Chemotherapy with L-Asparaginase, Lomustine, and Prednisone for Relapsed or Refractory Canine Lymphoma. <i>Journal of Veterinary Internal Medicine</i> , 2007 , 21, 127-132	3.1	45
152	Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. <i>PLoS ONE</i> , 2015 , 10, e0124889	3.7	43
151	Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone. <i>BMC Veterinary Research</i> , 2008 , 4, 32	2.7	43
150	Serum 25-hydroxyvitamin D concentrations in dogs - correlation with health and cancer risk. <i>Veterinary and Comparative Oncology</i> , 2016 , 14, 295-305	2.5	42
149	Expression and function of survivin in canine osteosarcoma. <i>Cancer Research</i> , 2012 , 72, 249-59	10.1	41
148	Mast Cell Tumors 2013 , 335-355		40
147	Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 367-78	7.4	38
146	Changes in cell shape are correlated with metastatic potential in murine and human osteosarcomas. <i>Biology Open</i> , 2016 , 5, 289-99	2.2	38
145	Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma. <i>PLoS ONE</i> , 2012 , 7, e37239	3.7	37
144	Biological and molecular characterization of a canine hemangiosarcoma-derived cell line. <i>Research in Veterinary Science</i> , 2006 , 81, 76-86	2.5	37
143	Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors. <i>Journal of Veterinary Internal Medicine</i> , 2012 , 26, 135-41	3.1	36
142	Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma. <i>Veterinary and Comparative Oncology</i> , 2013 , 11, 306-15	2.5	36
141	Combination chemotherapy with continuous L-asparaginase, lomustine, and prednisone for relapsed canine lymphoma. <i>Journal of Veterinary Internal Medicine</i> , 2009 , 23, 1058-63	3.1	36
140	Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol. <i>Veterinary and Comparative Oncology</i> , 2016 , 14 Suppl 1, 147-55	2.5	35

139	Systems biology approach to identification of biomarkers for metastatic progression in cancer. <i>BMC Bioinformatics</i> , 2008 , 9 Suppl 9, S8	3.6	33
138	A randomized trial investigating the efficacy and safety of water soluble micellar paclitaxel (Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell tumors in dogs. <i>Journal of Veterinary Internal Medicine</i> , 2012 , 26, 598-607	3.1	31
137	Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation. <i>Clinical Cancer Research</i> , 2010 , 16, 1498-508	12.9	31
136	HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors. <i>BMC Veterinary Research</i> , 2013 , 9, 130	2.7	30
135	Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. <i>PLoS Genetics</i> , 2018 , 14, e1007589	6	30
134	Canine sarcomas as a surrogate for the human disease. <i>Pharmacology & Therapeutics</i> , 2018 , 188, 80-96	13.9	29
133	Serum vascular endothelial growth factor concentrations and postsurgical outcome in dogs with osteosarcoma. <i>Veterinary and Comparative Oncology</i> , 2008 , 6, 126-32	2.5	29
132	The Flint Animal Cancer Center (FACC) Canine Tumour Cell Line Panel: a resource for veterinary drug discovery, comparative oncology and translational medicine. <i>Veterinary and Comparative Oncology</i> , 2017 , 15, 481-492	2.5	27
131	Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. <i>BMC Veterinary Research</i> , 2015 , 11, 131	2.7	26
130	Retrospective evaluation of doxorubicin-piroxicam combination for the treatment of transitional cell carcinoma in dogs. <i>Journal of Small Animal Practice</i> , 2013 , 54, 67-74	1.6	25
129	Comparative analysis of survivin expression in untreated and relapsed canine lymphoma. <i>Journal of Veterinary Internal Medicine</i> , 2008 , 22, 989-95	3.1	25
128	Human granulocyte-macrophage colony-stimulating factor DNA cationic-lipid complexed autologous tumour cell vaccination in the treatment of canine B-cell multicentric lymphoma. <i>Veterinary and Comparative Oncology</i> , 2007 , 5, 219-31	2.5	25
127	Genomic instability and telomere fusion of canine osteosarcoma cells. <i>PLoS ONE</i> , 2012 , 7, e43355	3.7	25
126	Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study. <i>Veterinary and Comparative Oncology</i> , 2010 , 8, 188-95	2.5	24
125	Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 4832-42	12.9	24
124	Four-fraction radiation therapy for macroscopic soft tissue sarcomas in 16 dogs. <i>Journal of the American Animal Hospital Association</i> , 2008 , 44, 100-8	1.3	23
123	Plasma synthesis of carbon magnetic nanoparticles and immobilization of doxorubicin for targeted drug delivery. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2004 , 15, 1033-49	3.5	23
122	Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumors. <i>Cancer Immunology, Immunotherapy</i> , 2003 , 52, 473-80	7.4	22

121	Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?. <i>Journal of Veterinary Internal Medicine</i> , 2005 , 19, 732-6	3.1	22
120	c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine. <i>Journal of Veterinary Internal Medicine</i> , 2018 , 32, 394-405	3.1	22
119	Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder. <i>Veterinary and Comparative Oncology</i> , 2017 , 15, 1417-1427	2.5	21
118	Diagnosis and management of lymphoma in a green iguana (Iguana iguana). <i>Journal of the American Veterinary Medical Association</i> , 2011 , 239, 985-91	1	21
117	Multiple distinct malignancies in dogs: 53 cases. <i>Journal of the American Animal Hospital Association</i> , 2010 , 46, 20-30	1.3	21
116	Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. <i>Journal of Veterinary Internal Medicine</i> , 2007 , 21, 113-20	3.1	21
115	Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma. <i>Journal of Veterinary Internal Medicine</i> , 2014 , 28, 1569-74	3.1	20
114	Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study. <i>Veterinary Journal</i> , 2012 , 191, 131-4	2.5	20
113	Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia [®]) in canine mast cell tumor. <i>BMC Veterinary Research</i> , 2014 , 10, 105	2.7	20
112	Dose-escalating vinblastine for the treatment of canine mast cell tumour. <i>Veterinary and Comparative Oncology</i> , 2008 , 6, 111-9	2.5	20
111	Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma. <i>Veterinary and Comparative Oncology</i> , 2018 , 16, E23-E29	2.5	19
110	Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 671-82	3.5	19
109	Elevated serum thymidine kinase activity in canine splenic hemangiosarcoma*. <i>Veterinary and Comparative Oncology</i> , 2012 , 10, 292-302	2.5	19
108	Immunohistochemical characterization of feline oral squamous cell carcinoma. <i>American Journal of Veterinary Research</i> , 2012 , 73, 1801-6	1.1	19
107	An orthotopic, postsurgical model of luciferase transfected murine osteosarcoma with spontaneous metastasis. <i>Clinical and Experimental Metastasis</i> , 2010 , 27, 151-60	4.7	19
106	Click Conjugation of Cloaked Peptide Ligands to Microbubbles. <i>Bioconjugate Chemistry</i> , 2018 , 29, 1534-1543	3.3	18
105	A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma. <i>Journal of Cellular Biochemistry</i> , 2012 , 113, 773-83	4.7	18
104	Lung tumor development and spontaneous regression in lambs coinfecting with Jaagsiekte sheep retrovirus and ovine lentivirus. <i>Veterinary Pathology</i> , 2010 , 47, 148-62	2.8	18

103	Aftershocks of cancer chemotherapy: managing adverse effects. <i>Journal of the American Animal Hospital Association</i> , 2007 , 43, 1-7	1.3	17
102	Successful Treatment of Acute Tumor Lysis Syndrome in a Dog with Multicentric Lymphoma. <i>Journal of Veterinary Internal Medicine</i> , 2007 , 21, 1401-1404	3.1	17
101	Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma. <i>Journal of Veterinary Internal Medicine</i> , 2017 , 31, 872-878	3.1	16
100	Cyclooxygenase-2 expression in equine tumors. <i>Veterinary Pathology</i> , 2008 , 45, 825-8	2.8	16
99	Serum concentrations of cardiac troponin I and cardiac troponin T in dogs with class IV congestive heart failure due to mitral valve disease. <i>Journal of Veterinary Emergency and Critical Care</i> , 2007 , 17, 243-249	1.7	16
98	Intrinsic Radiosensitivity and Cellular Characterization of 27 Canine Cancer Cell Lines. <i>PLoS ONE</i> , 2016 , 11, e0156689	3.7	16
97	Spontaneously Occurring Tumors in Companion Animals as Models for Drug Development 2004 , 259-284		16
96	Phase II clinical evaluation of lomustine chemotherapy for feline vaccine-associated sarcoma. <i>Veterinary and Comparative Oncology</i> , 2012 , 10, 283-91	2.5	15
95	Pharmacokinetic modeling of doxorubicin pharmacokinetics in dogs deficient in ABCB1 drug transporters. <i>Journal of Veterinary Internal Medicine</i> , 2010 , 24, 579-86	3.1	15
94	Comparative oncology approach to drug repurposing in osteosarcoma. <i>PLoS ONE</i> , 2018 , 13, e0194224	3.7	14
93	Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs. <i>Journal of Veterinary Internal Medicine</i> , 2015 , 29, 1098-104	3.1	14
92	NOD/SCID mouse model of canine T-cell lymphoma with humoral hypercalcaemia of malignancy: cytokine gene expression profiling and in vivo bioluminescent imaging. <i>Veterinary and Comparative Oncology</i> , 2008 , 6, 39-54	2.5	13
91	Canine Cancer: Strategies in Experimental Therapeutics. <i>Frontiers in Oncology</i> , 2019 , 9, 1257	5.3	13
90	Canine Cutaneous Plasmacytosis: 21 Cases (2005-2015). <i>Journal of Veterinary Internal Medicine</i> , 2017 , 31, 1074-1080	3.1	12
89	Prognostic significance of circulating microRNA-214 and -126 in dogs with appendicular osteosarcoma receiving amputation and chemotherapy. <i>BMC Veterinary Research</i> , 2019 , 15, 39	2.7	12
88	Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses. <i>Veterinary and Comparative Oncology</i> , 2018 , 16, E76-E82	2.5	12
87	GS-9219/VDC-1101--a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma. <i>BMC Veterinary Research</i> , 2014 , 10, 30	2.7	12
86	Comparison of fluid types for resuscitation after acute blood loss in mallard ducks (<i>Anas platyrhynchos</i>). <i>Journal of Veterinary Emergency and Critical Care</i> , 2009 , 19, 467-72	1.7	12

85	Glucose transporter 1 expression in canine osteosarcoma. <i>Veterinary and Comparative Oncology</i> , 2008 , 6, 133-40	2.5	12
84	Impact of telomerase status on canine osteosarcoma patients. <i>Journal of Veterinary Internal Medicine</i> , 2008 , 22, 1366-72	3.1	12
83	Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 49, 251-5	3.5	12
82	Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma. <i>Journal of Veterinary Internal Medicine</i> , 2007 , 21, 127-32	3.1	12
81	Liposome-encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats. <i>Journal of Veterinary Internal Medicine</i> , 2002 , 16, 726-31	3.1	12
80	The effect of Zhangfei/CREBZF on cell growth, differentiation, apoptosis, migration, and the unfolded protein response in several canine osteosarcoma cell lines. <i>BMC Veterinary Research</i> , 2015 , 11, 22	2.7	11
79	Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling. <i>BMC Veterinary Research</i> , 2019 , 15, 276	2.7	11
78	Disease distribution in canine patients with acanthocytosis: 123 cases. <i>Veterinary Clinical Pathology</i> , 2013 , 42, 465-70	1	11
77	Veterinary oncology clinical trials: design and implementation. <i>Veterinary Journal</i> , 2015 , 205, 226-32	2.5	11
76	Diagnostic accuracy of pre-treatment biopsy for grading soft tissue sarcomas in dogs. <i>Veterinary and Comparative Oncology</i> , 2014 , 12, 106-13	2.5	11
75	Epidermal growth factor enhances the malignant phenotype in canine mammary carcinoma cell lines. <i>Veterinary and Comparative Oncology</i> , 2011 , 9, 196-206	2.5	11
74	RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target. <i>Melanoma Research</i> , 2010 , 20, 35-42	3.3	11
73	Novel Treatments for Lymphoma. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2019 , 49, 903-915	2.4	10
72	Primary osteosarcoma of the synovium in a dog. <i>Journal of the American Animal Hospital Association</i> , 2000 , 36, 326-31	1.3	10
71	Prospective evaluation of flow cytometric characteristics, histopathologic diagnosis and clinical outcome in dogs with naïve B-cell lymphoma treated with a 19-week CHOP protocol. <i>Veterinary and Comparative Oncology</i> , 2020 , 18, 342-352	2.5	10
70	<i>Proteus mirabilis</i> inhibits cancer growth and pulmonary metastasis in a mouse breast cancer model. <i>PLoS ONE</i> , 2017 , 12, e0188960	3.7	9
69	Prognostic and predictive significance of KIT protein expression and c-kit gene mutation in canine cutaneous mast cell tumours: A consensus of the Oncology-Pathology Working Group. <i>Veterinary and Comparative Oncology</i> , 2019 , 17, 451-455	2.5	9
68	The creation of the Comparative Oncology Trials Consortium Pharmacodynamic Core: Infrastructure for a virtual laboratory. <i>Veterinary Journal</i> , 2010 , 185, 88-9	2.5	9

67	Interactions between radiation therapy and immunotherapy: the best of two worlds?. <i>Veterinary and Comparative Oncology</i> , 2006 , 4, 189-97	2.5	9
66	Clinical, Pathological, and Ethical Considerations for the Conduct of Clinical Trials in Dogs with Naturally Occurring Cancer: A Comparative Approach to Accelerate Translational Drug Development. <i>ILAR Journal</i> , 2018 , 59, 99-110	1.7	9
65	Expression of Phosphorylated KIT in Canine Mast Cell Tumor. <i>Veterinary Pathology</i> , 2017 , 54, 387-394	2.8	8
64	Geographical differences in survival of dogs with non-Hodgkin lymphoma treated with a CHOP based chemotherapy protocol. <i>Veterinary and Comparative Oncology</i> , 2017 , 15, 1564-1571	2.5	8
63	The immunosignature of canine lymphoma: characterization and diagnostic application. <i>BMC Cancer</i> , 2014 , 14, 657	4.8	8
62	Optofluidic intracavity spectroscopy of canine hemangiosarcoma. <i>IEEE Transactions on Biomedical Engineering</i> , 2011 , 58, 853-60	5	8
61	Hematopoietic Tumors 2019 , 688-772		8
60	Prognostic value of fluorine flourodeoxyglucose positron emission tomography/computed tomography in dogs with appendicular osteosarcoma. <i>Journal of Veterinary Internal Medicine</i> , 2019 , 33, 820-826	3.1	7
59	Pilot study utilizing Fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography for glycolytic phenotyping of canine mast cell tumors. <i>Veterinary Radiology and Ultrasound</i> , 2018 , 59, 461-468	1.2	7
58	DNA repair deficiency as a susceptibility marker for spontaneous lymphoma in golden retriever dogs: a case-control study. <i>PLoS ONE</i> , 2013 , 8, e69192	3.7	7
57	Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastine. <i>Veterinary and Comparative Oncology</i> , 2020 , 18, 169-175	2.5	7
56	Induction of VEGF by tepoxalin does not lead to increased tumour growth in a canine osteosarcoma xenograft. <i>Veterinary and Comparative Oncology</i> , 2011 , 9, 118-30	2.5	6
55	Plasma synthesis of carbon-iron magnetic nanoparticles and immobilization of doxorubicin for targeted drug delivery. <i>Journal of Materials Engineering and Performance</i> , 2006 , 15, 376-382	1.6	6
54	Survivin inhibition via EZN-3042 in canine lymphoma and osteosarcoma. <i>Veterinary and Comparative Oncology</i> , 2016 , 14, e45-57	2.5	6
53	Novel acyclic nucleotide analogues GS-343074 and GS-424044 demonstrate antiproliferative and pro-apoptotic activity in canine neoplastic cell lines. <i>Veterinary and Comparative Oncology</i> , 2015 , 13, 246-254	2.5	5
52	Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs. <i>Journal of Veterinary Internal Medicine</i> , 2020 , 34, 882-889	3.1	5
51	Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials. <i>Veterinary and Comparative Oncology</i> , 2020 , 18, 763-769	2.5	5
50	Characterization of a low expression haplotype in canine glutathione S-transferase (GSTT1) and its prevalence in golden retrievers. <i>Veterinary and Comparative Oncology</i> , 2018 , 16, E61-E67	2.5	5

49	Relative biological effectiveness in canine osteosarcoma cells irradiated with accelerated charged particles. <i>Oncology Letters</i> , 2016 , 12, 1597-1601	2.6	5
48	In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma. <i>PLoS ONE</i> , 2018 , 13, e0200634	3.7	5
47	Development of a limited-sampling model for prediction of doxorubicin exposure in dogs. <i>Veterinary and Comparative Oncology</i> , 2014 , 12, 114-9	2.5	5
46	Interleukin-11 receptor alpha is expressed on canine osteosarcoma. <i>Veterinary and Comparative Oncology</i> , 2010 , 8, 96-102	2.5	5
45	Auranofin improves overall survival when combined with standard of care in a pilot study involving dogs with osteosarcoma. <i>Veterinary and Comparative Oncology</i> , 2020 , 18, 206-213	2.5	5
44	Inertial focusing of circulating tumor cells in whole blood at high flow rates using the microfluidic CTCKey device for CTC enrichment. <i>Lab on A Chip</i> , 2021 , 21, 3559-3572	7.2	5
43	Epithelial Cell Adhesion Molecule Expression in Canine Tumours. <i>Journal of Comparative Pathology</i> , 2016 , 155, 299-304	1	4
42	Postsurgical Outcome in Cats with Exocrine Pancreatic Carcinoma: Nine Cases (2007-2016). <i>Journal of the American Animal Hospital Association</i> , 2018 , 54, 291-295	1.3	4
41	In vitro antineoplastic effects of auranofin in canine lymphoma cells. <i>BMC Cancer</i> , 2018 , 18, 522	4.8	4
40	Malignant mesenchymoma with widespread metastasis including bone marrow involvement in a dog. <i>Veterinary Clinical Pathology</i> , 2014 , 43, 447-52	1	4
39	Vinorelbine rescue therapy for dogs with primary urinary bladder carcinoma. <i>Veterinary and Comparative Oncology</i> , 2015 , 13, 443-51	2.5	4
38	What is your diagnosis? A soft-tissue mass in the thoracic cavity between the heart and the right crus of the diaphragm. <i>Journal of the American Veterinary Medical Association</i> , 2000 , 216, 23-4	1	4
37	Improving reporting of clinical trials in veterinary medicine. <i>Journal of Veterinary Internal Medicine</i> , 2010 , 24, 799-800; author reply 801-2	3.1	3
36	Drug dose and drug choice: Optimizing medical therapy for veterinary cancer. <i>Veterinary and Comparative Oncology</i> , 2020 , 18, 143-151	2.5	3
35	Adjuvant carboplatin for treatment of splenic hemangiosarcoma in dogs: Retrospective evaluation of 18 cases (2011-2016) and comparison with doxorubicin-based chemotherapy. <i>Journal of Veterinary Internal Medicine</i> , 2021 , 35, 1929-1934	3.1	3
34	Successful treatment of acute tumor lysis syndrome in a dog with multicentric lymphoma. <i>Journal of Veterinary Internal Medicine</i> , 2007 , 21, 1401-4	3.1	3
33	Bacterial Killing Activity of Polymorphonuclear Myeloid-Derived Suppressor Cells Isolated From Tumor-Bearing Dogs. <i>Frontiers in Immunology</i> , 2019 , 10, 2371	8.4	2
32	Spontaneous Companion Animal (Pet) Cancers 2011 , 353-373		2

31	Surface Modification of Positive Contrast Nanoparticle Agents with RAFT Polymers Towards the Targeted Imaging and Treatment of Cancer. <i>ACS Symposium Series</i> , 2010 , 65-101	0.4	2
30	Cancer of the Gastrointestinal Tract 2020 , 432-491		2
29	Predicting likelihood of in vivo chemotherapy response in canine lymphoma using ex vivo drug sensitivity and immunophenotyping data in a machine learning model. <i>Veterinary and Comparative Oncology</i> , 2021 , 19, 160-171	2.5	2
28	Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma. <i>Clinical Cancer Research</i> , 2021 ,	12.9	2
27	Transverse mode analysis of optofluidic intracavity spectroscopy of canine hemangiosarcoma 2010 ,		1
26	Cytotoxic chemotherapy: new players, new tactics. <i>Journal of the American Animal Hospital Association</i> , 2005 , 41, 209-14	1.3	1
25	Mast Cell Tumors 2019 , 382-403		1
24	Miscellaneous Tumors 2019 , 773-810		1
23	Substitution of mitoxantrone for doxorubicin in a multidrug chemotherapeutic protocol for first-line treatment of dogs with multicentric intermediate- to large-cell lymphoma. <i>Journal of the American Veterinary Medical Association</i> , 2019 , 254, 236-242	1	1
22	Multicenter, randomized, double-blinded, placebo-controlled study of rabacfosadine in dogs with lymphoma.. <i>Journal of Veterinary Internal Medicine</i> , 2021 ,	3.1	1
21	Phase-I trial of survivin inhibition with EZN-3042 in dogs with spontaneous lymphoma. <i>BMC Veterinary Research</i> , 2020 , 16, 97	2.7	0
20	Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma. <i>Communications Biology</i> , 2021 , 4, 1178	6.7	0
19	Biological behaviour of primary osteosarcoma of the digits, metacarpal and metatarsal bones in dogs. <i>Veterinary and Comparative Oncology</i> , 2021 , 19, 735-742	2.5	0
18	Tumor aggressiveness is independent of radiation quality in murine hepatocellular carcinoma and mammary tumor models. <i>International Journal of Radiation Biology</i> , 2021 , 97, 1140-1151	2.9	0
17	Canine Non-Angiogenic, Non-Myogenic Splenic Stromal Sarcoma: a Retrospective Clinicopathological Analysis and Investigation of Podoplanin as a Marker of Tumour Histogenesis. <i>Journal of Comparative Pathology</i> , 2021 , 188, 1-12	1	0
16	What Is Your Diagnosis? Renal adenocarcinoma. <i>Journal of the American Veterinary Medical Association</i> , 2015 , 247, 247-9	1	
15	What is your diagnosis? Extraskelatal osteosarcoma. <i>Journal of the American Veterinary Medical Association</i> , 2012 , 240, 265-6	1	
14	Possible cardiotoxicity associated with low-dose doxorubicin during chemotherapy in a ring-tailed lemur (<i>Lemur catta</i>) with multicentric lymphoma. <i>Veterinary Record Case Reports</i> ,	0.2	

- 13 GS-9219 - A Novel Prodrug of the Acyclic Nucleotide PMEG Demonstrates Significant Therapeutic Activity Against Spontaneous Non-Hodgkin Lymphoma as Modeled in Pet Dogs.. *Blood*, **2007**, 110, 1380-1380 2.2
- 12 GS-9219 - A Novel Prodrug of the Acyclic Nucleotide PMEG Has Antitumor Activity Against Naive and Melphalan-Refractory Spontaneous Myeloma in Pet Dogs.. *Blood*, **2007**, 110, 1508-1508 2.2
- 11 Development of Masitinib for the Treatment of Peripheral T-Cell Lymphoma. *Blood*, **2015**, 126, 3993-3993 2.2
- 10 Abstract A56: Canine Mast Cell Tumor and Toceranib Phosphate (Palladia) Development of a Spontaneous Canine Model of Kinase Inhibitor Resistance. *Clinical Cancer Research*, **2012**, 18, A56-A56 12.9
- 9 Assessment of the Chemotherapy Patient 37-56
- 8 Chemotherapy Agents 93-99
- 7 Management of Chemotherapy Side Effects 101-112
- 6 Dispelling the Myths of Animal Cancer and Its Treatment 1-14
- 5 There and back again: Translating adoptive cell therapy to canine cancer and improving human treatment. *Veterinary and Comparative Oncology*, **2021**, 19, 420-427 2.5
- 4 Prospective clinical trial testing COXEN-based gene expression models of chemosensitivity in dogs with spontaneous osteosarcoma. *Cancer Chemotherapy and Pharmacology*, **2021**, 88, 699-712 3.5
- 3 Molecular/Targeted Therapy of Cancer **2019**, 251-285
- 2 Clinical Trials and Developmental Therapeutics **2019**, 340-351
- 1 Canine lymphoma in 1914. *Veterinary and Comparative Oncology*, **2021**, 19, 1-2 2.5